VISFATIN AND CARDIOVASCULAR PROTECTION
Abstract
In cardiovascular diseases, visfatin was initially proposed as a marker of atherosclerosis, endothelial dysfunction, and vascular damage. Objectives: we try to elucidate the relationship between visfatin and cardiovascular diseases as different controversial studies about visfatin role were found. Data sources: we summarized the contents of 251 research and review articles from different web sites till 31 January 2013. Summary of content of the article: in this review, we summarized the role of visfatin in different cardiovascular diseases and we explain the mechanism of action in different conditions. We discussed the relationship between visfatin, obesity and cardiovascular functions as this triad is considered in different situations. Moreover, we discussed the effect of visfatin on blood pressure and the potential role of visfatin in blood pressure control. We also mentioned briefly the role of visfatin in pre-eclampsia. In addition, we discussed in more details the role of visfatin in cardioprotection and the mechanism of action. Finally we summarized the role of visfatin in renin angiotensin system and its potential usage in clinical pharmacology. Conclusion: we found that visfatin has a great beneficial effect in protecting the heart in different situations as well as its relaxing effect on blood vessels is of great value in hypertension. We also concluded that visfatin has a lipid lowering effect in different situations including metabolic syndrome and type 2 diabetes mellitus. The role of visfatin in cardiovascular diseases could be implemented in clinical drug therapy which need further human studies.DOI
https://doi.org/10.22270/jddt.v4i2.806Published
14-03-2014
Statistics
Abstract Display: 358
PDF Downloads: 447
PDF Downloads: 447
How to Cite
1.
Rezk MY. VISFATIN AND CARDIOVASCULAR PROTECTION. J. Drug Delivery Ther. [Internet]. 2014 Mar. 14 [cited 2025 Jan. 17];4(2):154-66. Available from: https://jddtonline.info/index.php/jddt/article/view/806
Issue
Section
Review
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
1.
Rezk MY. VISFATIN AND CARDIOVASCULAR PROTECTION. J. Drug Delivery Ther. [Internet]. 2014 Mar. 14 [cited 2025 Jan. 17];4(2):154-66. Available from: https://jddtonline.info/index.php/jddt/article/view/806